Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this week titled “The Graft-versus-Host Disease Exchange - Expert Perspectives on Evolving Clinical Practice” with leading pediatric transplant and cellular-therapy specialist Dr. Susan Prockop, Associate Professor, Harvard Medical School; Attending Physician & Director, Boston Children's Hospital. Dr. Prockop provided an overview of Ryoncil® (remestemcel-L-rknd)1 as a new treatment paradigm in the management of acute graft-versus-host disease, its use as first line after steroids, highlighted case studies, and discussed results from pivotal trials.
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 95 stories mentioning NOV, the earliest published 16 Dec 2025.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.